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Taltirelin (TAL) is a thyrotropin-releasing hormone (TRH) analog that is approved for use in
humans in Japan. In this study, we characterizedTAL binding to and signaling by the human
TRH receptor (TRH-R) in a model cell system. We found that TAL exhibited lower binding
afﬁnities thanTRH and lower signaling potency via the inositol-1,4,5-trisphosphate/calcium
pathway thanTRH. However,TAL exhibited higher intrinsic efﬁcacy thanTRH in stimulating
inositol-1,4,5-trisphosphate second messenger generation. This is the ﬁrst study that elu-
cidates the pharmacology ofTAL atTRH-R and shows thatTAL is a superagonist at TRH-R.
We suggest the superagonism exhibited by TAL may in part explain its higher activity in
mediating central nervous system effects in humans compared to TRH.
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INTRODUCTION
Based on evidence that thyrotropin-releasing hormone (TRH)
modulates a number of central nervous system (CNS) activi-
ties including arousal, antidepressant activity, anxiolytic effects,
increase in locomotor activity, antagonism of pentobarbital-
induced sedation, thermoregulation, and cardiovascular and
gastrointestinal autonomic functions (Horita et al., 1986; Horita,
1998; Khomane et al., 2011), many analogs of TRH were synthe-
sized and studied. Taltirelin (TAL) hydrate [(1-methyl-(S)-4,5-
dihydroorotyl)-histidyl-prolinamide, TA-0910] is an analog that
showed improved CNS activity (Suzuki et al., 1990; Yamamura
et al., 1991, 1997) and lower thyrotropin (TSH)-releasing activity
(Yamamura et al., 1997) compared to TRH in rodents. Based on
these characteristics, TAL was studied as a treatment for neurode-
generative disorders and is the only TRH analog that has been
approved for use in humans; it is used in Japan to treat patients
with adult spinal muscular atrophy (Ceredist®).
In some mammals, including rodents, there are two subtypes
of G protein-coupled (or seven-transmembrane-spanning) recep-
tors for TRH. These are TRH receptor 1 (TRH-R1), which is
the primary (or only) receptor in TSH-secreting cells, and TRH-
R2, which is expressed throughout the CNS along with TRH-R1
but typically in different areas of the brain (O’Dowd et al., 2000;
Sun et al., 2003). In humans, by contrast, only a single type of
receptor for TRH, TRH-R, is expressed that is more similar to
TRH-R1 than TRH-R2 (Duthie et al., 1993; Matre et al., 1993). It
has been reported that TAL binds with lower afﬁnity than TRH
to receptors in rat or mouse pituitary and in brain tissue prepara-
tions (Kinoshita et al., 1997; Asai et al., 1999, 2005). However, the
pharmacology of TAL at TRH-R has not been characterized.
In this study, we characterized TAL binding and signaling by




Dulbecco’s modiﬁed Eagle’s medium (DMEM) and fetal bovine
serum were purchased from Biosource (Rockville, MD, USA).
TRH (pyroGlu-His-ProNH2) and MeTRH (pGlu-His(1(τ )-
methyl)-ProNH2) were purchased from Sigma (St. Louis, MO,
USA). [3H]MeTRH was purchased from PerkinElmer (Waltham,
MA, USA). TAL (N-[[(4S)-Hexahydro-1-methyl-2,6-dioxo-4-
pyrimidinyl]carbonyl]-L-histidyl-L-prolinamide) was obtained
from Tocris (San Diego, CA, USA).
CELL CULTURE AND GENERATION OF CELLS STABLY
EXPRESSING TRH-R
HEK-EM 293 (human embryonic kidney) cells stably expressing
TRH-R were generated as follows. The human TRH-R cDNA
in pcDNA3.1(+) was obtained from the Missouri S&T cDNA
Resource Center (Rolla, MO, USA) and was subcloned into
the pcDNA3.1(+)/hygromycin vector. HEK-EM 293 cells were
transfected with the cDNA of TRH-R using FuGENE 6 transfec-
tion reagent (Roche Diagnostics GmbH, Mannheim, Germany)
and the cell clones stably expressing TRH-R were selected using
hygromycin (250 μg/ml). HEK-EM 293 cells stably expressing
TRH-Rwere grown inDMEMcontaining 10% fetal bovine serum,
100 U/ml penicillin, 10 μg/ml streptomycin, and 200 μg/ml
hygromycin B (Invitrogen, Carlsbad, CA, USA) at 37◦C in a
humidiﬁed 5% CO2 incubator.
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COMPETITION BINDING
Competition binding assays were performed in monolayers of
intact HEK cells expressing TRH-Rs. The cells (220,000 cells/well
in 24-well plates) were preincubated with various concentrations
of unlabeled TAL, TRH, or MeTRH for 15 min before addi-
tion of radioligand and then incubated at 37◦C for 1 h with
4 nM [3H]MeTRH as described elsewhere (Engel et al., 2006).
Non-speciﬁc binding was determined in incubations with excess
non-radiolabeled MeTRH. IC50 is the concentration of unlabeled
ligand that reduces speciﬁc binding of [3H]MeTRH by 50%.
The receptor number per cell was calculated from competition
binding curves of various doses of unlabeled MeTRH and 4 nM
[3H]MeTRH (Figure 1) and found to be 16,000/cell.
MEASUREMENT OF INTRACELLULAR CALCIUM MOBILIZATION
Cells stably expressing TRH-R were seeded in black-walled, clear-
bottomed 96-well plates (Corning, NY, USA) at a density of
60,000 cells/well in DMEM with 10% fetal bovine serum and
incubated for 24 h at 37◦C in 5% CO2. The following day, the
culture media was replaced with 100 μl of Hank’s balanced salt
solution with 20 mM HEPES, pH 7.5 and the cells were loaded
with 100μl of calcium 4 ﬂuorescent dye (Molecular Devices, Sun-
nyvale, CA, USA) for 1 h at room temperature before addition of
compounds. Transient changes in intracellular [Ca++] induced
by TAL, TRH, or MeTRH were measured using the FLIPRTETRA
system (Molecular Devices, Sunnyvale, CA, USA). Changes in ﬂu-
orescence were detected at the emission wavelength ranges from
515 to 575 nm. The agonistic responses of ligands were assessed
FIGURE 1 | MeTRH binding and signaling via Ca2+ in cells expressing
TRH-Rs. Competition binding with [3H]MeTRH and changes in cytosolic
free Ca2+ concentration (Ca2+ release) were performed in intact HEK-EM
293 cells stably expressingTRH-Rs as described in Section “Materials and
Methods.” The competition binding data are presented as the % of
[3H]MeTRH bound to cells in the absence of unlabeled ligand (B0) and
represent the results from three experiments conducted with duplicate
measurements. Note the left axis is inverted. Intracellular Ca2+ release
data are shown as a % of the maximal Ca2+ increase over basal. The
curves represent the non-linear regression analyses of data obtained in one
of three experiments with triplicate measurements using a sigmoidal
dose–response method.
immediately upon their addition in a concentration range from
0.1 nM to 30 μM. Responses were measured as peak ﬂuores-
cent intensity minus basal ﬂuorescent intensity at each compound
concentration and are presented as % of the maximum response.
MEASUREMENT OF IP1 PRODUCTION
Cells were seeded at 220,000/well in white, solid bottom, tissue
culture-treated 24-well plates and cultured at 37◦C with 5% CO2
overnight. Serial dilutions of TAL, TRH, or MeTRH, in Hank’s
balanced salt solution with 20 mM HEPES and 50 mM LiCl, pH
7.4, were added at 200 μl/well on the second day. After 60 min
incubation at 37◦C in 5% CO2, inositol monophosphate (IP1)
content was measured using the IP-One ELISA kit (Cisbio Inter-
national, France) according to the manufacturer’s protocol. The
results were calculated as IP1 nanomoles/well and are presented as
% of the maximum response.
DATA ANALYSIS
The dose–response data were analyzed by non-linear regression of
curve ﬁt with one-site competition using GraphPad Prism soft-
ware version 4 (GraphPad, Inc., San Diego, CA, USA) and the
signiﬁcance was determined by t-test or ANOVA.
RESULTS
The pharmacology of TAL binding and signaling was studied in
HEK-EM 293 cells, which do not endogenously express TRH-Rs,
engineered to express 16,000 TRH-Rs/cell (Table 1). In competi-
tion binding assays using 4 nM [3H]MeTRH and various doses
of unlabeled MeTRH, the concentration of MeTRH that half-
maximally inhibited [3H]MeTRH binding (IC50) was 3.0 nM
(Figure 1). The half-maximally effective concentration (EC50) of
MeTRH for stimulating an increase in cytosolic Ca2+ concen-
tration (Ca2+ release) was 7.2 nM, which is not different from
the IC50 (p > 0.1). Thus, MeTRH is an agonist at TRH-R with
high potency. We compared the effects of TAL and TRH in com-
peting for [3H]MeTRH binding and on stimulating Ca2+ release
(Figure 2). The IC50 values were 910 and 36 nM for TAL and TRH,
respectively, and the EC50 values were 36 and 5.0 nM for TAL and
TRH, respectively. Thus, TRHwas a high potency agonist and TAL
was a moderate potency agonist at TRH-R. We noted, moreover,
that the IC50/EC50 ratio was 25 for TAL (p < 0.02), 7.2 for TRH
(p < 0.05), and approximately 0.4 for MeTRH. When comparing
two agonists, the agonist with the higher IC50/EC50 ratio has a
greater intrinsic efﬁcacy (Engel et al., 2006). These ﬁndings sug-
gested that TAL may be a more efﬁcacious agonist than TRH and
that TRH is more efﬁcacious than MeTRH.We previously showed
that TRH exhibited a higher intrinsic efﬁcacy than MeTRH at
Table 1 | Pharmacological parameters forTRH-R.
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FIGURE 2 |TAL andTRH binding and signaling via Ca2+ in cells
expressingTRH-Rs. Competition binding with [3H]MeTRH and changes in
cytosolic free Ca2+ concentration (Ca2+ release) were performed in intact
HEK-EM 293 cells stably expressingTRH-Rs as described in the legend to
Figure 1. The competition binding data are presented as the % of
[3H]MeTRH bound to cells in the absence of unlabeled ligand (B0) and
represent the results from three experiments conducted with duplicate
measurements. Note the left axis is inverted. Intracellular Ca2+ release
data are shown as a % of the maximal Ca2+ increase over basal. The
curves represent the non-linear regression analysis of data obtained in
three experiments with duplicate or triplicate measurements using a
sigmoidal dose–response method.
mouse TRH-Rs (Engel et al., 2006). As TRH is the natural, full
agonist, TAL is termed a superagonist, and MeTRH is a partial
agonist.
As Ca2+ release is a rapid and transient response to TRH-R
activation, it is easier to compare relative intrinsic efﬁcacies by
quantifying activationof the inositol-1,4,5-trisphosphate pathway.
Inositol-1,4,5-trisphosphate production is the step prior to Ca2+
release in signal transduction by TRH-Rs (Gershengorn, 1986)
and can be quantiﬁed by measuring accumulation of its metabolic
product IP1 over time by inhibiting IP1 degradation (Figure 3A).
The EC50 values for IP1 production were found to be 150 nM for
TAL and 3.9 nM for TRH.More importantly, TALwas clearlymore
efﬁcacious than TRH in that TAL stimulated an increase in IP1
production that was 180% of that stimulated by TRH (p < 0.001).
Another way of demonstrating relative intrinsic efﬁcacies of
agonists is to show that the maximal response of a more efﬁ-
cacious agonist is inhibited by a less efﬁcacious agonist (Engel
et al., 2006). Figure 3B illustrates the IP1 responses to maximally
effective doses of MeTRH, TRH, and TAL. As is evident, TAL (3.5-
fold over MeTRH) is more efﬁcacious than TRH (2.1-fold over
MeTRH); MeTRH is the least efﬁcacious. As predicted, the least
efﬁcacious agonist MeTRH inhibited the response to TRH (full
agonist) and to TAL (superagonist).
DISCUSSION
In this study, we characterized the binding and signaling prop-
erties of TAL at TRH-R that, to our knowledge, have not been
previously reported. The binding properties of TAL at rodent TRH
receptors have been studied previously (Asai et al., 1999; Brown,
1999). In agreement with the ﬁndings with rodent receptors, we
found that TAL binds to TRH-R with lower afﬁnity than TRH.
Our most interesting observation, however, is that TAL exhibits
higher intrinsic efﬁcacy than TRH; that is, TAL can stimulate the
same level of signaling as TRH but at lower levels of receptor occu-
pancy and could induce higher levels of signaling than TRH at full
occupancy (Figure 3). Since TRH is the natural, full agonist for
TRH-R,TAL is termed a superagonist.We previously reported that
other TRH analogs displayed higher intrinsic efﬁcacies than TRH
at rodent TRH receptors (Engel et al., 2006). In the same study,
we showed that MeTRH, the only TRH analog with higher afﬁnity
and potency than TRH, was a partial agonist that displayed lower
intrinsic efﬁcacy than TRH and that when high levels of TRH
and MeTRH were added simultaneously the level of signaling was
lowered to that of MeTRH. This is the predicted effect of adding a
FIGURE 3 |TAL is a superagonist atTRH-R. (A) IP1 production was
determined in HEK 293 cells expressingTRH-R in the presence of increasing
doses of TAL or TRH as described in Section “Materials and Methods.” The
data represent the mean of duplicate points from ﬁve experiments.
(B) MeTRH inhibits IP1 formation stimulated byTAL andTRH. IP1 production
was determined in the presence of TRH (0.1 μM), TAL (3 μM), MeTRH
(3 μM), TRH + MeTRH, or TAL + MeTRH. The data are expressed as
mean ± SEM performed in duplicate of two experiments.
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partial agonist along with a full agonist. We used a similar exper-
imental design herein to conﬁrm that TAL is a superagonist at
TRH-R; MeTRH antagonized IP1 production stimulated by both
TRH and TAL (Figure 3B).
Previous reports in rodents showed that TAL displayed more
activity in stimulating CNS effects than TRH (Suzuki et al., 1990;
Brown, 1999). TAL may have similar CNS effects in humans (Gary
et al., 2003; Khomane et al., 2011). The differences in the activities
of TAL and TRH in the CNS have been attributed to the higher
stability in blood and increased penetration of the blood–brain
barrier of TAL compared to TRH. Although this is likely true, our
new ﬁndings of the signaling efﬁcacy of TAL at TRH-R suggest
that the higher intrinsic efﬁcacy of TAL may be contributing to its
CNS activity in humans also.
In summary, we have described characterization of the phar-
macology of TAL at TRH-R. Most importantly, we showed that
TAL is a superagonist when signaling at TRH-R via the Gq/11
protein-phospholipase C-phosphatidylinositol-4,5-bisphosphate-
inositol-1,4,5-trisphosphate-calcium pathway. We suggest the
superagonism exhibited by TAL may, in addition to its relative
metabolic stability and ability to cross the blood–brain barrier,
explain its higher activity in mediating CNS effects in humans
compared to TRH.
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